{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-24-000031","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.397083+00:00","generated_at":"2026-06-03T22:27:42.705760+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"JNJ reports Q1 adjusted EPS $2.71 (+12.4% YoY); declares 4.2% dividend increase to $1.24/quarter","bullets":["Worldwide sales $21.38B, up 2.3% total (6.0% ex-COVID-19 vaccine); MedTech up 4.5%, Innovative Medicine ex-vaccine up 6.9%","GAAP net earnings from continuing ops $5.35B ($2.20 diluted EPS) vs $0.49B loss in prior year (large litigation charges skewed comparison)","Adjusted net earnings $6.58B, up 3.8%; adjusted diluted EPS $2.71 vs $2.41, +12.4%","Board raises quarterly dividend to $1.24/share (from $1.19), a 4.2% increase; marks 62nd consecutive annual increase","New indicated annual dividend $4.96/share; payable June 4, 2024 to holders of record May 21, 2024"],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-24-000031","json":"https://secwatch.observer/filing/0000200406-24-000031.json","markdown":"https://secwatch.observer/filing/0000200406-24-000031.md","text":"https://secwatch.observer/filing/0000200406-24-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040624000031/0000200406-24-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040624000031/jnj-20240416.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:27:42.705760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b18051dcda72d6bd2feddda6575c366cd37bab5","claim":"JOHNSON & JOHNSON reported first quarter ended March 31, 2024 results: revenue $21,383 million, net income $5,354 million, EPS $2.20.","evidence_excerpt":"On April 16, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040624000031/0000200406-24-000031-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$21,383 million"},{"label":"Net income","value":"$5,354 million"},{"label":"EPS","value":"$2.20"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}